The cell isolation market will register a CAGR of almost 19% by 2023
NEW YORK, June 11, 2019 /PRNewswire/ --
About this market
The rise in demand for clinical diagnosis is one of the key factors anticipated to drive the cell isolation market growth during the forecast period. To effectively treat various diseases using genetic engineering tools, early diagnosis is essential. Genetic engineering tools provide diagnostic enzymes such as cholesterol oxidase and xylitol oxidase. These diagnostic enzymes identify specific cells like cells with high levels of cholesterol. When blood levels of these particular enzymes increase significantly, it indicates a probable site for tissue damage, which releases these enzymes in the blood. These enzymes are used in assays using samples of serum or urine. The isolation of these enzymes can provide the required enzymes for clinical diagnosis. Thus, genetic engineering tools are useful, precise, and economical for researchers and healthcare providers to diagnose patients. Our analysts have predicted that the cell isolation market will register a CAGR of almost 19% by 2023.
Download the full report: https://www.reportbuyer.com/product/5778678/?utm_source=PRN
Market Overview
Increasing prevalence of chronic diseases
The growing incidences of chronic diseases have increased the need for cell-based therapies. Cell isolation is an important step in various experiments during diagnostics and research of chronic diseases. Cell isolation tools are increasingly used in drug discovery techniques to generate recombinant protein therapeutics, which can treat a variety of diseases, including cancer, autoimmune diseases, and genetic disorders. The wide applications of isolated human cells in research, drug development, and clinical trials are increasing with growing incidences of chronic diseases globally. Hence, the rising prevalence of chronic diseases increases the demand for cell-based therapies, which increases the demand for cell isolation tools.
Ethical issues regarding embryonic stem cell isolation
The high potential of stem cell-based therapy in clinical applications has encouraged researchers to use stem cell tools to treat genetic disorders in pharmacy genomics and regenerative medicines. However, clinical applications of stem cells raise some ethical and safety concerns regarding the extraction of human embryonic stem cells. The key issue lies with the destruction of a human embryo, which impedes the development of human embryonic stem cell-based clinical therapies.
For the detailed list of factors that will drive and challenge the growth of the cell isolation market during 2019-2023, view our report.
Competitive Landscape
The market appears to be fairly fragmented. The presence of several companies, including Agilent Technologies Inc. and Becton Dickinson and Co., makes the competitive environment quite intense. Several vendors are expected to participate in such strategic alliances to gain a competitive advantage, which will improve the availability of cell isolation products in the market. Merck KGaA, QIAGEN NV, and Thermo Fisher Scientific Inc. are some of the major companies covered in this report.
Download the full report: https://www.reportbuyer.com/product/5778678/?utm_source=PRN
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +1 (718) 213 4904
Website: www.reportbuyer.com
SOURCE ReportBuyer
Share this article